Clinical Efficacy and Prognostic Influence of Qikui Decoction in Adjuvant Chemotherapy for Advanced Non-Small Cell Lung Carcinoma

Jie Xu, Na Xiao, Hailang He and Xianmei Zhou

Background and Objective: Improving patient outcomes and treatment efficiency and increasing survival rate are still the hurdles that clinical workers need to solve. The purpose of this study was to inquire into the clinical efficacy and prognostic influence of Qikui decoction in adjuvant chemotherapy for advanced Non-Small Cell Lung Carcinoma (NSCLC). Materials and Methods: One hundred patients with advanced NSCLC who received chemotherapy with paclitaxel (PTX) and cisplatin (DDP) in hospitals were selected as the research participants. Among them, 50 patients were treated with PTX combined with DDP as a control group (CG) and another 50 patients were additionally given Qikui decoction during chemotherapy as an observation group (OG). The following items were observed in both arms: Clinical efficacy, adverse reactions (ARs), serum tumour markers (STMs), liver and kidney function, immune function, prognosis and survival. Results: After treatment, the curative effect was higher (p = 0.043) and the incidence of ARs (p = 0.032) was lower in OG as compared to CG, CEA, NSE and CYFRA211 decreased in both groups and were lower in OG (p<0.05), Scr, BUN and ALT reduced in both arms, with more evident reductions in OG (p<0.05), CD4⁺ and CD4⁺/CD8⁺ increased while CD⁸⁺ decreased in both arms (p<0.05) and the alterations were more obvious in OG (p<0.05), OG also showed better quality of life, prognosis and survival than CG (p<0.05). Conclusion: Qikui decoction in adjuvant chemotherapy for advanced NSCLC has a definite clinical effect and can improve the prognosis of patients.

View Fulltext Back